CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F19%3A10395562" target="_blank" >RIV/00179906:_____/19:10395562 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/19:10395562

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=mUklvY_dnd" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=mUklvY_dnd</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cells8050456" target="_blank" >10.3390/cells8050456</a>

Result language

angličtina

Original language name

CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate

Original language description

Background: Glatiramer acetate (GA) is an effective treatment for the earliest stages of multiple sclerosis (MS)clinically isolated syndrome (CIS) or clinically definite MS (CDMS). Objective: This study aims to determine the differences in the lymphocyte population (at baseline and the course of five years) between confirmed sustained progression (CSP) and non-CSP groups and to identify potential biomarkers among these parameters that can predict a positive response to the treatment. Methods: Twelve male and 60 female patients were included in the study. Peripheral blood samples were collected before and five years after treatment with GA. The authors compared lymphocyte parameters between the CSP and non-CSP groups by statistical analyses. Univariate and penalized logistic regression models were fitted to identify the best lymphocyte parameters at baseline and their combination for potential biomarkers. Subsequently, the ROC analysis was used to identify cut-offs for selected parameters. Results: The parameter CD4+/CD45RO+ was identified as the best single potential biomarker, demonstrating the ability to identify patients with CSP. Moreover, a combination of four lymphocyte parameters at baseline, relative lymphocyte counts, CD3+/CD69+, CD4+/CD45RO+, and CD4+/CD45RA+ab, was identified as a potential composite biomarker. This combination explains 23% of the variability in CSP, which is better than the best univariate parameter when compared to CD4+/CD45RO+ at baseline. Conclusions: The results suggest that other biomarkers can help monitor the conditions of patients and predict a favourable outcome.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

<a href="/en/project/EF17_048%2F0007441" target="_blank" >EF17_048/0007441: PERSONMED - Center for the Development of Personalized Medicine in Age-Related Diseases</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cells [online]

ISSN

2073-4409

e-ISSN

—

Volume of the periodical

8

Issue of the periodical within the volume

5

Country of publishing house

CH - SWITZERLAND

Number of pages

13

Pages from-to

456

UT code for WoS article

000470994400076

EID of the result in the Scopus database

—